• Home
  • » 
  • Reports
  • » 
  • Immune Checkpoint Inhibitors Market (2nd...

Immune Checkpoint Inhibitors Market

Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025

  • Lowest Price Guaranteed From USD 2,199

  • Published
    July 2015

  • Pages
    401

  • View Count
    8053

  • Buy Now

Example Insights

  1. The industry is characterized by the presence of three marketed drugs and 34 drugs in clinical development for oncological indications. The marketed and clinical pipeline includes two CTLA-4, nine PD-1 / PD-L1 and 26 novel Immune Checkpoint Inhibitors.The dynamic pipeline also includes several molecules in preclinical/ discovery stage; in our research, we identified about 70 such molecules.
  2. BMS, with tenImmune Checkpoint Inhibitors (marketed / under development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck & Co, Pfizer, Merck KGaA, Roche, GSK, Novartis and Amgen.
  3. Many start-ups, small companies and university spin-offs have also emerged in the past two years. Examples (in alphabetical order) include Agenus, Alligator Bioscience, Ambrx, AnaptysBio, arGEN-X, Bioceros, BioNovion, Cellerant Therapeutics, Checkpoint Therapeutics, Compugen, CureTech, Enumeral, Five Prime Therapeutics, Genmab, GITR, ImmuNext, IOmet Pharma, iTeos Therapeutics, Jounce Therapeutics, KAHR Medical, Multimeric Biotherapeutics, Nativis, Orega Biotech, Pelican Therapeutics, Pieris Pharmaceuticals, Prima BioMed, Redx Pharma, Sorrento Therapeutics,Tesaro, TG Therapeutics, Theravectys and ToleroTech.
  4. Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have gained maximum attention; this is followed by molecules targeting LAG-3, CD-70, OX-40 and CD-40. Although Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market.
  5. Collaborations have helped the market reach its current growth trajectory.Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; the period Jan 2014-May 2015 saw over 40 such collaborations for a number of molecules.
  6. We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2015 - 2025, our forecast suggests that the market will witness an annualized growth rate of 27.7%.

Report Description

Immune Checkpoint Inhibitors Market Overview

Cancer is known to be one of the leading causes of death worldwide. The field of oncology is vast and comprises several indications, including some rare / orphan forms. Although oncology continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body’s own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). Interest has surged in other classes of immunotherapeutics; these include Immune Checkpoint Inhibitors, therapeutic cancer vaccines and other whole cell based therapies.

Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and many under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform.With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period.

In addition to the marketed drugs (Yervoy, Opdivo and Keytruda), we expect a number of drugs currently in advanced stages of development (Tremelimumab, Elotuzumab, RG7446 and Avelumab)to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants.

Scope of the Report

The “Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025” report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for a broad range of cancer indications. Specifically, CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic commercially available until other classes recently stepped in. The recent approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market.

In addition, there are several novel checkpoint inhibitors (e.g. IDO, LAG-3, CD70, OX40, CD40, GITR, TIM-3, CD137/4-1BB, KIR, TDO, VISTA, CS1, NKG2A, GARP, ICOS) which have recently gained ground and are expected to retain attention in the future.

One of the key objectives of the study is to review the prospects laid by the robust, opportunistic and broad pipelines of the pharmaceutical firms. With three marketed drugs (Yervoy, Keytruda and Opdivo), the market is treading its way towards fulfilling the huge untapped promise. Amongst other elements, the report elaborates upon the following key areas:

  • The current state of the market with respect to key players, developmental stage of pipeline products (both clinical / pre-clinical) and indications targeted
  • Recent partnerships which have taken place over the last five years including product co-development, licensing and clinical trial collaborations
  • Combinationtherapies where Immune Checkpoint Inhibitors are being evaluated in combination with other anti-cancer agents/therapies
  • Various investments and grants received by the companies focused in this area
  • Competitive landscape and inherent threats to growth in the short and long term
  • Development and sales potential based on target consumer segments, likely adoption rate and expected pricing

The base year for the report is 2015. The report provides the market forecast for the period 2015-2025, respectively. The research, analysis and insights presented in this report include potential sales of several Immune Checkpoint Inhibitors; this analysis is backed by a deep understanding of key drivers behind the growth.

Owing to niche nature of the market, with most products in the pipeline, we have provided three market forecast scenarios to add robustness to our model. The conservative, base and optimistic scenarios represent three different tracks of industry evolution.All actual figures have been sourced and analyzed from publicly available information. The figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter Outlines

Chapter 2  presents an executive summary of the report. It offers a high level view on where the Immune Checkpoint Inhibitors market is headed in the mid-long term.

Chapter 3  provides a general introduction to Immune Checkpoint Inhibitors. In this section, we have briefly discussed the conventional therapies being used for oncology treatment, the advent of cancer immunotherapy and, specifically, the emergence of Immune Checkpoint Inhibitors.

Chapter 4  provides a comprehensive landscape of the Immune Checkpoint Inhibitors market. This chapter includes information on more than 100 inhibitors which are currently in different stages of development (both clinical and pre-clinical / discovery). The detailed analysis of this development pipeline includes information on types of molecules, most commonly targeted indications, current phases of development and the likely launch timelines.

Chapter 5  focuses on CTLA-4 inhibitors and presents the current scenario and the future outlook for this specific class of molecules. The chapter includes detailed drug profiles of the marketed and drugs under development. We have presented information on several parameters such as history of development, clinical trial results, manufacturing, cost and reimbursement. It includes the likely sales forecast of the drugs currently in advanced stage of development.

Chapter 6  focuses on PD-1 and PD-L1 inhibitors and presents the current scenario and the future outlook for this specific class of inhibitors. As with the CTLA-4 inhibitors, this chapter provides a holistic view on the various drugs belonging to this class and their future sales potential.

Chapter 7  focuses on novel inhibitors. Examples of these inhibitors include IDO, LAG-3, CD70, OX40, CD40, GITR, TIM-3, CD137/4-1BB, KIR, TDO, VISTA, CS1, NKG2A, GARP and ICOS. As in the earlier two chapters, we have provided detailed drug profiles and the future outlook for these new set of inhibitors.

Chapter 8  provides details on all the active/planned clinical studies evaluating Phase II/III/marketed Immune Checkpoint Inhibitors as combination therapies. The chapter focuses on the most common combinations, provides adetailed analysis of all the listed clinical studies and highlights the evolving preference of pharma companies in terms of differing combination classes.

Chapter 9  offers a comprehensive competitive landscape of various therapies being used for the treatment of certain oncological indications; these indications have been the prime focus of companies developing Immune Checkpoint Inhibitors. 

Chapter 10  includes an elaborate discussion on the various collaborations and partnerships which have been forged amongst the players in the market over the last several years.

Chapter 11  presents details on the various investments and grants received by the companies focused in the area of Immune Checkpoint Inhibitors. The analysis highlights the growing interest from the VC community and other strategic investors.

Chapter 12  provides detailed company profiles of the leading players in the market. Each company profile includes information such as financial performance, geographical presence, marketed / pipeline drugs and recent collaborations and developments.

Chapter 13  is a collection of transcripts of interviews conducted during the course of this study.

Chapter 14  summarises the overall report. In this chapter, we have provided a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.

Chapter 15  is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16  provides the list of companies mentioned in the report.

Table of Contents

1. Preface
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. Executive Summary
 
3. Cancer Therapeutics and Immuno-Oncology
3.1. Chapter Overview
3.2. The Four Pillars of Cancer Therapy
3.3. Immunotherapy: Gaining A Strong Foothold
3.3.1. Activation and Suppression Immunotherapies
3.4. Immuno-Oncology (Cancer Immunotherapy)
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.2. By Product Class
3.5.2.1. Monoclonal Antibodies (mAbs)
3.5.2.2. Cytokines
3.5.2.3. Cell Based Therapies
3.5.2.4. Immune Checkpoint Inhibitors
 
4. Current Market Landscape
4.1. Scope and Observations
4.2. Common Targets for Immune Checkpoint Inhibitors
4.3. Three Approved Immune Checkpoint Inhibitors in Market
4.4. Immune Checkpoint Inhibitors: Clinical and Preclinical Pipeline
4.4.1. Immune Checkpoint Inhibitors: Distribution by Drug Developers
4.4.2. Immune Checkpoint Inhibitors: Distribution by Targets
4.4.3. Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
4.4.4. Immune Checkpoint Inhibitors: Distribution by Type of Molecule
4.5. Overall Future Outlook: Sales Forecast, 2015 - 2025
4.5.1. Scope and Forecast Methodology
4.5.2. Overall Market Size and Forecast
 
5. CTLA-4 Inhibitors: Key Molecules and Future Outlook
5.1. CTLA-4 Inhibitors: Mechanism of Action
5.2. Pioneers of Immune Checkpoint Inhibitors Market
5.3. CTLA-4 Inhibitors: Pipeline Analysis
5.3.1. CTLA-4 Inhibitors: Distribution by Highest Phase of Development
5.3.2. CTLA-4 Inhibitors: Distribution by Type of Molecule
 
5.4. Yervoy / Ipilimumab (Bristol Myers Squibb)
5.4.1. Introduction
5.4.2. History of Development
5.4.3. Dosage and Manufacturing
5.4.4. Treatment Cost and Reimbursement
5.4.5. Current Status of Development
5.4.6. Key Clinical Trial Results
5.4.7. Historical Sales
5.4.8. Patent Expiry
5.4.9. Collaborations
5.4.10. Target Patient Population
5.4.11. Yervoy/ Ipilimumab Sales Forecast, 2015 – 2025
 
5.5. Tremelimumab (MedImmune)
5.5.1. Introduction
5.5.2. History of Development
5.5.3. Current Status of Development
5.5.4. Key Clinical Trial Results
5.5.5. Collaborations
5.5.6. Target Patient Population
5.5.7. Tremelimumab Sales Forecast, 2015 – 2025
 
5.6. CTLA-4 Inhibitors: Roots Analysis’ Perspective
 
6. PD-1 and PD-L1 Inhibitors: Key Molecules and Future Outlook
6.1. PD-1/PD-L1 Inhibitors: Mechanism of Action
6.2. Two Recent Launches Have Strengthened the Market Sentiment
6.3. PD-1 / PD-L1 Inhibitors: Pipeline Analysis
6.3.1. PD-1 / PD-L1 Inhibitors: Landscape Analysis
6.3.2. PD-1 / PD-L1 Inhibitors: Distribution by Target
6.3.3. PD-1 / PD-L1 Inhibitors: Distribution by Highest Phase of Development
6.3.4. PD-1 / PD-L1 Inhibitors: Distribution by Type of Molecule
 
6.4. Opdivo/Nivolumab (Bristol Myers Squibb)
6.4.1. Introduction
6.4.2. History of Development
6.4.3. Dosage and Manufacturing
6.4.4. Treatment Cost and Reimbursement
6.4.5. Current Status of Development
6.4.6. Key Clinical Trial Results
6.4.6.1. Metastatic Melanoma (Single Agent)
6.4.6.2. NSCLC
6.4.6.3. Advanced Melanoma (Combination Therapy)
6.4.6.4. Hodgkin Lymphoma
6.4.6.5. RCC
6.4.6.6. Hepatocellular Carcinoma
6.4.7. Historical Sales
6.4.8. Patent Expiry
6.4.9. Collaborations
6.4.10. Target Patient Population
6.4.11. Opdivo /Nivolumab Sales Forecast, 2015 – 2025
 
6.5. Keytruda / Pembrolizumab (Merck)
6.5.1. Introduction
6.5.2. History of Development
6.5.3. Dosage and Manufacturing
6.5.4. Treatment Cost and Reimbursement
6.5.5. Current Status of Development
6.5.6. Key Clinical Trial Results
6.5.8.1. Advanced Melanoma
6.5.8.2. NSCLC
6.5.8.3. Advanced Solid Tumors
6.5.8.4. Hodgkin Lymphoma
6.5.8.5. Advanced Head and Neck Cancer
6.5.8.6. Advanced Bladder Cancer
6.5.8.7. Advanced Gastric Cancer
6.5.8.8. Metastatic Breast Cancer
6.5.7. Historical Sales
6.5.8. Patent Expiry
6.5.9. Collaborations
6.5.10. Target Patient Population
6.5.11. Keytruda / Pembrolizumab Sales Forecast, 2015 – 2025
 
6.6. MPDL3280A/RG7446 (Roche)
6.6.1. Introduction
6.6.2. History of Development
6.6.3. Current Status of Development
6.6.4. Key Clinical Trial Results
6.6.4.1. NSCLC
6.6.4.2. Metastatic Bladder Cancer
6.6.4.3. Metastatic Breast Cancer
6.6.4.4. Metastatic Renal Cell Carcinoma
6.6.5. Collaborations
6.6.6. Target Patient Population
6.6.7. MPDL3280A/RG7446 Sales Forecast, 2015 – 2025
 
6.7. MEDI4736 (MedImmune)
6.7.1. Introduction
6.7.2. Current Status of Development
6.7.3. Key Clinical Trial Results
6.7.4. Collaborations
6.7.5. Target Patient Population
6.7.6. MEDI4736 Sales Forecast, 2015 – 2025
 
6.8. Avelumab/MSB0010718C (Merck KGaA/Pfizer)
6.8.1. Introduction
6.8.2. Current Status of Development
6.8.3. Key Clinical Trial Results
6.8.4. Collaborations
6.8.5. Target Patient Population
6.8.6. Avelumab /MSB0010718C Sales Forecast, 2015-2025
 
6.9. Pidilizumab/ CT-011 (CureTech)
6.9.1. Introduction
6.9.2. Current Status of Development
6.9.3. Key Clinical Trial Results
6.9.3.1. Metastatic Melanoma
6.9.3.2. B-cell Lymphoma
6.9.3.3. Relapsed Follicular Lymphoma
6.9.4. Target Patient Population
6.9.5. Collaborations
 
6.10. PD -1 and PD- L1 Inhibitors: Roots Analysis’ Perspective
 
7. Novel Immune Checkpoint Inhibitors: Key Molecules and Future Outlook
7.1. Rush for the Novel Immune Checkpoints
7.2. Novel Immune Checkpoint Inhibitors: Pipeline Analysis
7.2.1. Novel Immune Checkpoint Inhibitors: Distribution by Target
7.2.2. Novel Immune Checkpoint Inhibitors: Distribution by Companies
7.2.3. Novel Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
7.2.4. Novel Immune Checkpoint Inhibitors: Distribution by Type of Molecule
 
7.3. Elotuzumab (Bristol Myers Squibb/AbbVie)
7.3.1. Introduction
7.3.2. Mechanism of Action
7.3.3. History of Development
7.3.4. Current Status of Development
7.3.5. Key Clinical Trial Results
7.3.6. Collaborations
7.3.7. Target Patient Population
7.3.8. Elotuzumab Sales Forecast, 2015– 2025
 
7.4. Epacadostat/INCB024360 (Incyte Corporation)
7.4.1. Introduction
7.4.2. Mechanism of Action
7.4.3. Manufacturing
7.4.4. Current Status of Development
7.4.5. Key Clinical Trial Results
7.4.6. Target Patient Population
7.4.7. Collaborations
 
7.5. Indoximod (NewLink Genetics)
7.5.1. Introduction
7.5.2. Mechanism of Action
7.5.3. Manufacturing
7.5.4. Current Status of Development
7.5.5. Key Clinical Trial Results
7.5.6. Patent Information
7.5.7. Target Patient Population
7.5.8. Collaborations
 
7.6. Lirilumab (Bristol Myers Squibb)
7.6.1. Introduction
7.6.2. Mechanism of Action
7.6.3. Current Status of Development
7.6.4. Key Clinical Trial Results
7.6.5. Target Patient Population
7.6.6. Collaborations
 
7.7. IPH2201 (Innate Pharma)
7.7.1. Introduction
7.7.2. Mechanism of Action
7.7.3. Current Status of Development
7.7.4. Key Clinical Trial Results
7.7.5. Target Patient Population
7.7.6. Collaborations
 
7.8. Novel Checkpoint Inhibitors: Roots Analysis’ Perspective
 
8. Immune Checkpoint Inhibitors as Combination Therapy
8.1. Introduction
8.2. Combination Therapy: History of Development
8.3. FDA approved Combination Therapies in Oncology
8.4. Combination Therapies: FDA Guidelines
8.4.1. Combinations of Previously Marketed Drugs or Biologics
8.4.2. Combinations of Previously Marketed Drugs or Biologics with New Molecular Entities
8.4.3. Combinations of New Molecular Entities with New Molecular Entities
8.5. Combination Therapies: Immune Checkpoint Inhibitors
8.5.1. Immune Checkpoint Inhibitors Clinical Studies: Distribution by Type of Therapy Evaluation
8.5.2. Immune Checkpoint Inhibitors Combination Therapy Clinical Studies
8.5.2.1. Distribution by Highest Phase of Development
8.5.2.2. Distribution by Status
8.5.2.3. Distribution by Type of Immune Checkpoint Inhibitor
8.5.2.4. Distribution by Type of Combination Class
8.6. Combination of Immune Checkpoint Inhibitors with Immune Checkpoint Inhibitors
8.7. Combination of Immune Checkpoint Inhibitors with Chemotherapy
8.8. Combination of Immune Checkpoint Inhibitors with Kinase Inhibitors
8.9. Combination of Immune Checkpoint Inhibitors with Angiogenesis Inhibitors
8.10. Combination of Immune Checkpoint Inhibitors with Cancer Vaccine
8.11. Combination of Immune Checkpoint Inhibitors with Cytokines
8.12. Combination of Immune Checkpoint Inhibitors with Radiotherapy
8.13. Combination of Immune Checkpoint Inhibitors with Surgery
8.14. Combination of Immune Checkpoint Inhibitors with Oncolytic Virus Immunotherapy
8.15. Combination of Immune Checkpoint Inhibitors with Cell Based Immunotherapy
8.16. Combination of Immune Checkpoint Inhibitors with Hormone Therapy
8.17. Combination of Immune Checkpoint Inhibitors with Other Drug Classes
 
9. Competition in Key Indication Areas
9.1. Chapter Overview
9.2. Competition in Melanoma Market
9.3. Competition in Malignant Mesothelioma Market
9.4. Competition in NSCLC Market
9.5. Competition in Multiple Myeloma Market
9.6. Competition in Ovarian Cancer Market
9.7. Competition in Bladder Cancer Market
9.8. Competition in Kidney Cancer Market
 
10. Deals and Partnerships
10.1. Chapter Overview
10.2. Collaborations Inked in Immune Checkpoint Inhibitors Market
10.2.1. Distribution by Type
10.2.2. Distribution by Year of Partnership
10.3. Large Pharmaceutical Companies Acquiring to Expand Pipelines
10.4. Co-development and/or Commercialization Agreements
10.5. Product Licensing Agreements
10.6. Clinical Trial Collaborations to Validate Combination Therapies
10.6.1. Clinical Trial Collaborations: Distribution by Target
10.6.2. BMS and Merck Have Been the Most Active In Forging Clinical Trial Collaborations
10.7. Contract Manufacturing Agreement
10.8. Research Collaborations
 
11. Venture Capital Support
11.1. Chapter Overview
11.2. Instances of Investments / Grants in Immune Checkpoint Inhibitors Market
11.3. Growing Venture Capitalist Interest
11.4. Distribution of the Funding Instances on the Basis of Type of Funding
11.5. Distribution by Total Amount of Investment in a Category
 
12. Company Profiles
12.1. Chapter Overview
12.2. Bristol Myer Squibb
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.2.4. Collaborations
 
12.3. Merck & Co.
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.3.4. Collaborations
 
12.4. AstraZeneca
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.4.4. Collaborations
 
12.5. Roche / Genentech
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.5.4. Collaborations
 
12.6. Pfizer
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.6.4. Collaborations
 
12.7. Incyte Corporation
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.7.4. Collaborations
 
12.8. NewLink Genetics
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.8.4. Collaborations
 
12.9. Innate Pharma
12.9.1. Company Overview
12.9.2. Financial Performance
12.9.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.9.4. Collaborations
 
12.10. CureTech
12.10.1. Company Overview
12.10.2. Immune Checkpoint Inhibitors Pipeline, 2015
12.10.3. Collaborations
 
12.11. Celldex Therapeutics
12.11.1. Company Overview
12.11.2. Financial Performance
12.11.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.11.4. Collaborations
 
12.12. arGEN-X
12.12.1. Company Overview
12.12.2. Technology Platforms
12.12.3. Financial Performance
12.12.4. Immune Checkpoint Inhibitors Pipeline, 2015
12.12.5. Collaborations
 
12.13. Seattle Genetics
12.13.1. Company Overview
12.13.2. Technology Platforms
12.13.3. Financial Performance
12.13.4. Immune Checkpoint Inhibitors Pipeline, 2015
12.13.5. Collaborations
 
12.14. MacroGenics
12.14.1. Company Overview
12.14.2. Technology Platforms
12.14.3. Financial Performance
12.14.4. Immune Checkpoint Inhibitors Pipeline, 2015
12.14.5. Collaborations
 
12.15. GlaxoSmithKline
12.15.1. Company Overview
12.15.2. Financial Performance
12.15.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.15.4. Collaborations
 
12.16. GITR, Inc.
12.16.1. Company Overview
12.16.2. Immune Checkpoint Inhibitors Pipeline, 2015
12.16.3. Collaborations
 
12.17. Agenus
12.17.1. Company Overview
12.17.2. Financial Performance
12.17.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.17.4. Collaborations
 
12.18. Compugen
12.18.1. Company Overview
12.18.2. Financial Performance
12.18.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.18.4. Collaborations
 
12.19. Tesaro
12.19.1. Company Overview
12.19.2. Immune Checkpoint Inhibitors Pipeline, 2015
12.19.3. Collaborations
 
12.20. BioNovion
12.20.1. Company Overview
12.20.2. Technology Platform
12.20.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.20.4. Collaborations
 
12.21. IOmet Pharma
12.21.1. Company Overview
12.21.2. Immune Checkpoint Inhibitors Pipeline, 2015
 
12.22. Enumeral Biomedical Holdings
12.22.1. Company Overview
12.22.2. Technology Platform
12.22.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.22.4. Financial Performance
12.22.5. Collaborations
 
12.23 Immutep (PrimaBioMed)
12.23.1. Company Overview
12.23.2. Technology Platform
12.23.3. Immune Checkpoint Inhibitors Pipeline, 2015
12.23.4. Collaborations
 
13. Conclusion
13.1. Immune Checkpoint Inhibitors: A New Hope For Cancer Patients
13.2. Current Flag Bearers: PD-1 and PD-L1
13.3. Active Collaborations Likely To Be The Key To Future Success
13.4. With Several Blockbusters In The Pipeline, The Overall Opportunity Is Huge
13.5. Concluding Remarks
 
14. Interview Transcripts
 
15. Appendix: Tabulated Data
 
16. Appendix: List of Companies and Organizations

List of Figures

Figure 3.1 The Four Pillars of Cancer Therapy
Figure 3.2  Passive and Active Cancer Immunotherapies
Figure 4.1 Immune Checkpoint Inhibitors: Distribution by Drug Developers
Figure 4.2 Immune Checkpoint Inhibitors: Distribution by Targets
Figure 4.3 Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
Figure 4.4 Immune Checkpoint Inhibitors: Distribution by Type of Molecule
Figure 4.5  Immune Checkpoint Inhibitors: Overall Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Figure 5.1 CTLA-4 Inhibitors: Distribution by Highest Phase of Development
Figure 5.2  CTLA-4 Inhibitors: Distribution by Type of Molecule
Figure 5.3 Yervoy / Ipilimumab Sales, 2011 -  2014 (USD Million)
Figure 5.4  Yervoy / Ipilimumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Figure 5.5 Tremelimumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Figure 5.6 CTLA-4 Inhibitors: Drivers and Restraints
Figure 6.1  PD-1 / PD-L1 Inhibitors: Distribution by Drug Developer
Figure 6.2 PD-1 / PD-L1 Inhibitors: Distribution by Target
Figure 6.3 PD-1 / PD-L1 Inhibitors: Distribution by Highest Phase of Development
Figure 6.4 PD-1 / PD-L1 Inhibitors: Distribution by Type of Molecule
Figure 6.5 Opdivo / Nivolumab Sales, 2014- Q1 2015 (USD Million)
Figure 6.6  Opdivo / Nivolumab Sales Forecast, 2015–2025: Base Scenario (USD Million)
Figure 6.7 Keytruda / Pembrolizumab Sales, 2014 - Q1 2015(USD Million)
Figure 6.8  Keytruda / Pembrolizumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Figure 6.9  MPDL3280A/RG7446 Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Figure 6.10  MEDI4736 Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Figure 6.11  Avelumab / MSB0010718C Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Figure 6.12 PD-1 and PD-L1 Inhibitors: Drivers and Restraints
Figure 7.1  Novel Immune Checkpoint Inhibitors Pipeline: Distribution by Target
Figure 7.2  Novel Immune Checkpoint Inhibitors Pipeline: Distribution by Companies
Figure 7.3  Novel Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
Figure 7.4  Novel Immune Checkpoint Inhibitors: Distribution by Type of Molecule
Figure 7.5 Elotuzumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Figure 7.6 Novel Immune Checkpoint Inhibitors: Drivers and Restraints
Figure 8.1  Immune Checkpoint Inhibitors Clinical Studies: Distribution by Type of Therapy Evaluation
Figure 8.2 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
Figure 8.3 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Status
Figure 8.4 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Type of Immune Checkpoint Inhibitor
Figure 8.5 Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Type of Combination Class
Figure 10.1  Collaborations Inked in Immune Checkpoint Inhibitors Market: Distribution by Type
Figure 10.2  Collaborations Inked in Immune Checkpoint Inhibitors Market: Distribution by Year of Partnership
Figure 10.3 Clinical Trial Collaborations: Distribution by Target
Figure 11.1  Immune Checkpoint Inhibitors Funding Instances: Cumulative Investments by Year, 2001–2015
Figure 11.2  Immune Checkpoint Inhibitors Funding Instances: Distribution by Categories
Figure 11.3 Immune Checkpoint Inhibitors Funding Instances: Distribution by Amount Invested in a Category (USD Million)
Figure 12.1  BMS Revenues, 2011 - Q1 2015 (USD Billion)
Figure 12.2  BMS Revenues: Distribution by Therapeutic Areas, 2013 – 2014 (USD Million)
Figure 12.3  Merck Revenues, 2009 - Q1 2015 (USD Million)
Figure 12.4  Merck Revenues: Distribution by Business Segment, 2014 (USD Billion)
Figure 12.5 AstraZeneca Revenues, 2009 - Q1 2015(USD Million)
Figure 12.6 AstraZeneca Revenues: Distribution by Therapeutic Areas, 2013 -2014(USD Million)
Figure 12.7  Roche Revenues, 2009-Q1 2015 (CHF Billion)
Figure 12.8  Roche Revenues: Distribution by Business Segments, 2012 - 2014 (CHF Billion)
Figure 12.9 Roche Pharmaceutical Revenues: Distribution by Therapeutic Areas, 2014 (CHF Billion)
Figure12.10  Pfizer Revenues, 2011 - Q1 2015 (USD Billion)
Figure 12.11 Pfizer Revenues: Distribution by Business Segments, 2014 (USD Million)
Figure 12.12  Pfizer Revenues: Distribution by Therapeutic Areas, 2013 - 2014, (USD ‘000)
Figure 12.13  Incyte Corporation Revenues, 2011 - Q1 2015 (USD Million)
Figure 12.14  NewLink Genetics Revenues, 2011 - Q1 2015 (USD Million)
Figure 12.15  Innate Pharma Revenues, 2011 - Q1 2015 (EUR Million)
Figure 12.16  Celldex Therapeutics Revenues, 2011 - Q1 2015 (USD Million)
Figure 12.17  Seattle Genetics Revenues, 2011 - Q1 2015 (USD Million)
Figure 12.18  MacroGenics Revenues, 2011 - Q1 2015 (USD Million)
Figure12.19  GSK Revenues, 2009 - Q1 2015 (GBP Billion)
Figure12.20  GSK Pharmaceutical and Vaccine Revenues: Distribution by Business Domains 2014, (GBP Billion)
Figure12.21 Compugen Revenues, 2012 - Q1 2015 (USD Million)
Figure 12.22  Enumeral Revenues, 2013 - Q1 2015 (USD ‘000)
Figure 13.1 Immune Checkpoint Inhibitors Market (USD Billion), 2015, 2020 and 2025

List of Tables

Table 3.1 FDA Approved Antibody Based Therapeutics for Cancer
Table 4.1  Co-Stimulatory Molecules as Target for Immune Checkpoint Inhibition
Table 4.2  Immune Checkpoint Inhibitors: Marketed and Clinical Pipeline, 2015
Table 4.3  Immune Checkpoint Inhibitors: Preclinical and Discovery Pipeline, 2015
Table 4.4 Immune Checkpoint Inhibitors: Current Development Phase and Expected Launch Year of Drugs
Table 5.1 Pipeline of CTLA-4 Inhibitors, 2015
Table 5.2 Yervoy /Ipilimumab: History of Development
Table 5.3 Yervoy /Ipilimumab: Dosage and Packaging
Table 5.4 Yervoy /Ipilimumab: Current Status of Development
Table 5.5 Tremelimumab: Current Status of Development
Table 6.1  Pipeline of PD-1 and PD-L1 Inhibitors, 2015
Table 6.2 PD-1 /  PD-L1 Inhibitors: Landscape Analysis
Table 6.3 Opdivo/Nivolumab: Dosage and Packaging
Table 6.4 Opdivo/Nivolumab: Current Status of Development
Table 6.5  Keytruda / Pembrolizumab: Current Status of Development
Table 6.6  MPDL3280A / RG7446: Current Status of Development
Table 6.7 MEDI4736: Current Status of Development
Table 6.8 Avelumab / MSB0010718C: Current Status of Development
Table 6.9 Pidilizumab / CT-011: Current Status of Development
Table 6.10 Pidilizumab / CT-011: Investigator Sponsored Clinical Studies
Table 7.1  Pipeline of Novel Immune Checkpoint Inhibitors, 2015
Table 7.2 Elotuzumab: Current Status of Development
Table 7.3 Epacadostat / INCB024360: Current Status of Development
Table 7.4 Indoximod: Current Status of Development
Table 7.5 NewLink Genetics: Patent Portfolio Related to IDO Inhibitors
Table 7.6 Lirilumab: Current Status of Development
Table 8.1 FDA Approved Combination Therapies in Oncology, 2001-2015
Table 8.2 Combination of Immune Checkpoint Inhibitors with Immune Checkpoint Inhibitors
Table 8.3  Combination of Immune Checkpoint Inhibitors with Chemotherapy
Table 8.4 Combination of Immune Checkpoint Inhibitors with Kinase Inhibitors
Table 8.5 Combination of Immune Checkpoint Inhibitors with Chemotherapy
Table 8.6 Combination of Immune Checkpoint Inhibitors with Cancer Vaccine
Table 8.7 Combination of Immune Checkpoint Inhibitors with Cytokines
Table 8.8 Combination of Immune Checkpoint Inhibitors with Radiotherapy
Table 8.9 Combination of Immune Checkpoint Inhibitors with Surgery
Table 8.10 Combination of Immune Checkpoint Inhibitors with Oncolytic Virus Immunotherapy
Table 8.11 Combination of Immune Checkpoint Inhibitors with Cell Based Immunotherapy
Table 8.12 Combination of Immune Checkpoint Inhibitors with Hormone Therapy
Table 8.13 Combination of Immune Checkpoint Inhibitors with Other Drug Classes
Table 9.1 Comparison of Marketed Targeted Therapeutics for Melanoma
Table 9.2 Comparison of Marketed Targeted Therapeutics for Metastatic NSCLC
Table 9.3  Comparison of Marketed Therapeutics for Multiple Myeloma
Table 9.4 Comparison of Marketed Therapeutics for Renal Cell Carcinoma
Table 10.1 Immune Checkpoint Inhibitors Market: Acquisitions
Table 10.2 Immune Checkpoint Inhibitors Market: Co-Development and / or Commercialization Agreements
Table 10.3 Immune Checkpoint Inhibitors Market: Product Licensing Agreements
Table 10.4 Immune Checkpoint Inhibitors Market: Clinical Trial Collaborations
Table 10.5 Immune Checkpoint Inhibitors Market: Contract Manufacturing Agreements
Table 10.6 Immune Checkpoint Inhibitors Market: Research Collaborations
Table 11.1  List of Funding Rounds / Grants and Investors Involved
Table 12.1  BMS: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.2  BMS: Immune Checkpoint Inhibitors Partnerships
Table 12.3  Merck: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.4  Merck: Immune Checkpoint Inhibitors Partnerships
Table 12.5  AstraZeneca / MedImmune: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.6  AstraZeneca / MedImmune: Immune Checkpoint Inhibitors Partnerships
Table 12.7  Roche / Genentech: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.8  Roche / Genentech: Immune Checkpoint Inhibitors Partnerships
Table 12.9  Pfizer: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.10 Pfizer: Immune Checkpoint Inhibitors Partnerships
Table 12.11  Incyte Corporation: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.12  Incyte Corporation: Immune Checkpoint Inhibitors Partnerships
Table 12.13 NewLink Genetics: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.14  NewLink Genetics: Immune Checkpoint Inhibitors Partnerships
Table 12.15  Innate Pharma: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.16  Innate Pharma: Immune Checkpoint Inhibitors Partnerships
Table 12.17  CureTech: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.18  Celldex Therapeutics: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.19 Celldex Therapeutics: Immune Checkpoint Inhibitors Partnerships
Table 12.20  arGEN-X: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.21 arGEN-X: Immune Checkpoint Inhibitors Partnerships
Table 12.22 Seattle Genetics: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.23  MacroGenics: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.24  GSK: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.25 GITR: Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.26 Agenus Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.27  Agenus: Immune Checkpoint Inhibitors Partnerships
Table 12.28  Compugen Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.29  Compugen: Immune Checkpoint Inhibitors Partnerships
Table 12.30  Tesaro Immune Checkpoint Inhibitors Pipeline, 2015
Table 12.31  Tesaro: Immune Checkpoint Inhibitors Partnerships
Table 12.32  BioNovion Immune Checkpoint Inhibitors Pipeline, 2015 
Table 12.33 BioNovion: Immune Checkpoint Inhibitors Partnerships
Table 12.34 Immutep(Prima Biomed) Immune Checkpoint Inhibitors Pipeline, 2015
Table 15.1  Immune Checkpoint Inhibitors: Distribution by Drug Developers
Table 15.2  Immune Checkpoint Inhibitors: Distribution by Targets
Table 15.3  Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
Table 15.4  Immune Checkpoint Inhibitors: Distribution by Type of Molecule
Table 15.5  Immune Checkpoint Inhibitors: Overall Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.6  Immune Checkpoint Inhibitors: Overall Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.7  Immune Checkpoint Inhibitors: Overall Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
Table 15.8  CTLA-4 Inhibitors: Distribution by Highest Phase of Development
Table 15.9  CTLA-4 Inhibitors: Distribution by Type of Molecule
Table 15.10  Yervoy Sales, 2011 – 2014(USD Million)
Table 15.11  Yervoy /Ipilimumab Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.12  Yervoy /Ipilimumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.13  Yervoy /Ipilimumab Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
Table 15.14  Tremelimumab Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.15 Tremelimumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.16 Tremelimumab Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
Table 15.17  PD-1 / PD-L1 Inhibitors: Distribution by Drug Developer
Table 15.18  PD-1 / PD-L1Inhibitors: Distribution by Target
Table 15.19 PD-1 / PD-L1 Inhibitors: Distribution by Highest Phase of Development
Table 15.20  PD-1 / PD-L1Inhibitors: Distribution by Type of Molecule
Table 15.21 Opdivo / Nivolumab Sales, 2014- Q1 2015(USD Million)
Table 15.22  Opdivo / Nivolumab Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.23  Opdivo / Nivolumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.24  Opdivo / Nivolumab Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
Table 15.24  Keytruda / Pembrolizumab Sales, 2014-Q1 2015(USD Million)
Table 15.25  Keytruda /Pembrolizumab Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.26  Keytruda /Pembrolizumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.27  Keytruda /Pembrolizumab Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
Table 15.28  MPDL3280A/RG7446 Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.29  MPDL3280A/RG7446 Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.30  MPDL3280A/RG7446 Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
Table 15.31  MEDI4736 Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.32  MEDI4736 Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.33  MEDI4736 Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
Table 15.34  Avelumab / MSB0010718C Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.35  Avelumab / MSB0010718C Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.36  Avelumab / MSB0010718C Sales Forecast, 2015 - 2025: Optimistic Scenario (USD Million)
Table 15.37  Novel Immune Checkpoint Inhibitors Pipeline: Distribution by Target
Table 15.38  Novel Immune Checkpoint Inhibitors Pipeline: Distribution by Companies
Table 15.39  Novel Immune Checkpoint Inhibitors: Distribution by Highest Phase of Development
Table 15.40  Novel Immune Checkpoint Inhibitors: Distribution by Type of Molecule
Table 15.41  Elotuzumab Sales Forecast, 2015 - 2025: Base Scenario (USD Million)
Table 15.42  Elotuzumab Sales Forecast, 2015 - 2025: Conservative Scenario (USD Million)
Table 15.43  Elotuzumab Sales Forecast, 2015 - 2025: Optimistic  Scenario (USD Million)
Table 15.44  Immune Checkpoint Inhibitors Clinical Studies: Distribution by Type of Therapy Evaluation
Table 15.45  Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
Table 15.46  Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Status of Development
Table 15.47  Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Type of Immune Checkpoint Inhibitor
Table 15.48  Immune Checkpoint Inhibitors Combination Therapy Clinical Studies: Distribution by Type of Combination Class
Table 15.49  Collaborations Inked in Immune Checkpoint Inhibitors Market: Distribution by Type
Table 15.50  Collaborations Inked in Immune Checkpoint Inhibitors Market: Distribution by Year of Partnership
Table 15.51  Clinical Trial Collaborations: Distribution by Target
Table 15.52  Immune Checkpoint Inhibitors Funding Instances: Cumulative Investments by Year, 2001 - 2015
Table 15.53  Immune Checkpoint Inhibitors Funding Instances: Distribution by Categories
Table 15.54  Immune Checkpoint Inhibitors Funding Instances: Distribution by Amount Invested in a Category (USD Million)
Table 15.55  BMS Revenues, 2011 - Q1 2015 (USD Billion)
Table 15.56  BMS Revenues: Distribution by Therapeutic Areas, 2013 -2014(USD Million)
Table 15.57  Merck Revenues, 2009 - Q1 2015 (USD Million)
Table 15.58  Merck Revenues: Distribution by Business Segment, 2014 (USD Billion)
Table 15.59  AstraZeneca Revenues, 2009 - Q1’2015(USD Million)
Table 15.60  AstraZeneca Revenues: Distribution by Therapeutic Areas, 2013 -2014(USD Million)
Table 15.61  Roche Revenues, 2009 - Q120154 (CHF Billion)
Table 15.62  Roche Revenues: Distribution by Business Segments, 2012 - 2014 (CHFBillion)
Table 15.63  Roche Pharmaceutical Revenues: Distribution by Therapeutic Areas, 2014 (CHF Billion)
Table 15.64  Pfizer Revenues, 2011-Q1 2015 (USD Billion)
Table 15.65  Pfizer Revenues: Distribution by Business Segments, 2014 (USD Million)
Table 15.66  Pfizer Revenues: Distribution by Therapeutic Areas, 2013 - 2014, (USD ‘000)
Table 15.67  Incyte Corporation Revenues, 2011 - Q12015 (USD Million)
Table 15.68  NewLink Genetics Revenues, 2011 - Q1 2015(USD Million)
Table 15.69  Innate Pharma Revenues, 2011-Q1 2015(EUR Million)
Table 15.70  Celldex Therapeutics Revenues, 2011 - Q1 2015(USD Million)
Table 15.71  Seattle Genetics Revenues, 201 - Q1 2015(USD Million)
Table 15.72  MacroGenics Revenues, 2011 - Q1 2015(USD Million)
Table 15.73  GSK Revenues, 2009 - Q1 2015 (GBP Billion)
Table 15.74  GSK Pharmaceutical and Vaccine Revenues: Distribution by Business Domains 2014, (GBP Billion)
Table 15.75  Compugen Revenues, 2012 - Q1 2015 (USD Million)
Table 15.76  Enumeral Revenues, 2013 - Q1 2015 (USD ‘000)
Table 15.77  Immune Checkpoint Inhibitors Market (USD Billion), 2015, 2020 and 2025

Listed Companies

The following companies and organizations have been mentioned in the report.

  1. 4-Antibody
  2. 5 AM Ventures
  3. Abbott
  4. AbbVie
  5. Acerta Pharma BV
  6. Adimab
  7. Advanced Technology Ventures
  8. Advaxis
  9. Agenus
  10. AgonOX
  11. Alden Cancer Therapy II
  12. Alexandria Real Estate
  13. Allen & Company
  14. Alligator Bioscience
  15. Alloy Ventures
  16. Alta Partners
  17. Altor Bioscience
  18. Ambrx
  19. American Cancer Society
  20. American Society of Hematology
  21. Amgen
  22. Amplimmune
  23. AnaptysBio
  24. Anderson Cancer Center
  25. Aravis Ventures
  26. Arcus Ventures
  27. arGEN-X
  28. ARMO BioSciences
  29. AstraZeneca
  30. Aurigene
  31. Avalon Ventures
  32. Aventis
  33. Azienda Ospedaliera Universitaria Senese
  34. Banque Internationale
  35. Bayer
  36. BeiGene
  37. Belgian Walloon Government
  38. Belgium and BPI
  39. Beth Israel Deaconess Medical Center
  40. BioWa
  41. Bioceros
  42. Biogen Idec New Ventures
  43. BioGeneration Ventures
  44. BioInvent International AB
  45. Bio-Matrix Scientific Group
  46. BioNovion
  47. Boxer Capital of Tavistock Life Science
  48. Brabant Development Agency
  49. Brabant Life Sciences Seed Fund
  50. Bristol Myers Squibb
  51. Caisse de dpt et placement du Qubec
  52. California Pacific Medical Center Research Institute
  53. Camelot Ventures
  54. Cancer Research Institute
  55. Casdin Capital
  56. Celldex Therapeutics
  57. Cellerant Therapeutics
  58. Centocor Ortho Biotech
  59. Checkpoint Therapeutics
  60. Chiron
  61. CIDC
  62. CITIC Capital Holdings
  63. Clal Biotechnology Industries
  64. CMEA Capital
  65. Cogene BioTech Ventures
  66. Cold Genesys
  67. Compugen
  68. Cormorant Asset Management
  69. CoStim Pharmaceuticals
  70. Crédit Agricole Private Equity
  71. Curadev
  72. CureTech
  73. Curis
  74. CX Venture Group
  75. Dana-Farber Cancer Institute
  76. de Duve Institute
  77. Deerfield Management and Leerink Swann
  78. Dendreon
  79. Diamond Capital Company Ltd
  80. Domain Associates
  81. Dynavax Technologies
  82. Eddingpharm
  83. Eisai
  84. Eli Lilly and Company
  85. EMD Serono
  86. Emerging Technology Partners
  87. Eminent Venture Capital Corp
  88. Endocyte
  89. Enumeral Biomedical Holdings
  90. Erasmus MC Biomedical Fund
  91. ESCO Congress
  92. Ethe Erasmus Biomedical Fund
  93. European Regional Development Fund
  94. European Society for Medical Oncology
  95. Evogene
  96. Facet Biotech
  97. Fidelity Management & Research
  98. Five Prime Therapeutics
  99. Flexus Bioscience
  100. Forbion Capital Partners
  101. Foresite Capital
  102. Frazier Healthcare Partners
  103. Fred Hutchinson Cancer Research Center
  104. Genentech
  105. Genmab
  106. Genzyme
  107. George Rathmann
  108. Gilead
  109. GITR Inc.
  110. GlaxoSmithKline
  111. Grupo Español Multidisciplinar de Melanoma
  112. H. Lee Moffitt Cancer Center and Research Institute
  113. Hadasit Bio Holdings
  114. Harris & Harris Group
  115. Harvard University
  116. Healthcap Venture Capital
  117. HealthCare Ventures
  118. Heat Biologics
  119. Hillhouse Capital Group
  120. Hoffmann-La Roche
  121. Home Capital AS
  122. Hoosier Cancer Research Network
  123. Hunt Ventures
  124. Hunza Ventures SCA
  125. Imclone
  126. ImmuNext
  127. Immunocore
  128. ImmuTep
  129. Incyte Corporation
  130. Innate Pharma
  131. Innovis Investments
  132. Inserm Transfert Initiative
  133. Institut Bergonié
  134. Institute for the Promotion of Innovation by Science and Technology in Flanders
  135. InterWest Partners
  136. IOmet Pharma
  137. iTeos Therapeutics
  138. Janssen Biotech
  139. Johns Hopkins University
  140. Jonsson Comprehensive Cancer Center
  141. Jounce Therapeutics
  142. Juno Therapeutics
  143. Kadmon Corporation
  144. KAHR Medical
  145. KBC Securities
  146. Keddem Bioscience
  147. Kleiner Perkins Caufield & Byers
  148. Kyowa Hakko Kirin
  149. Laureate Pharma
  150. Lee's Pharmaceutical
  151. Ludwig Cancer Research
  152. Life Sciences Partners
  153. Lonza Biologics
  154. Ludwig Institute for Cancer Research
  155. M.D. Anderson Cancer Center
  156. MacroGenics
  157. Malmsten Invest
  158. Mark Tompkins Montrose Capital
  159. Masonic Cancer Center
  160. Massachusetts Institute of Technology
  161. Maverick Capital
  162. Medarex
  163. Medicare
  164. MedImmune
  165. Medivation
  166. Melanoma Institute, Australia
  167. Memorial Sloan Kettering Cancer Center
  168. Merck & Co
  169. Merck KGaA
  170. Merck Serono Ventures
  171. Mithra Ventures
  172. Mitsubishi UFJ
  173. MorphoSys
  174. Morphotek
  175. MPM Capital
  176. Multimeric Biotherapeutics
  177. NantWorks
  178. National Cancer Institute
  179. National Institutes of Health
  180. Nativis
  181. NCIC Clinical Trials Group
  182. Neviah Genomics
  183. New Enterprise Associates
  184. New York University School of Medicine
  185. NewLink Genetics
  186. Nextech Venture
  187. Nordic Venture Capital Investor Sunstone Capital
  188. Northwest Regional Development Agency
  189. Novartis
  190. Novel Bioventures
  191. Novo Nordisk
  192. Numenor Ventures
  193. Octalfa
  194. Ohio State University Comprehensive Cancer Center
  195. Omega Funds
  196. Oncothyreon
  197. Ono Pharmaceuticals
  198. Onyx Pharmaceuticals
  199. OPKO Health
  200. Oracle Partners
  201. OrbiMed
  202. Orega Biotech
  203. Organon
  204. Orphan Medical
  205. Pappas Ventures
  206. PDL Biopharma
  207. Pelican Therapeutics
  208. Pfizer
  209. Pharmacyclics
  210. Pharmstandard
  211. Pieris Pharmaceuticals
  212. Pierre Fabre
  213. Plexxikon
  214. Prima BioMed
  215. Prometheus Laboratories
  216. Providence Health & Services
  217. Ragon Institute of Massachusetts General Hospital
  218. Recipharm
  219. Red Abbey Venture Partners
  220. Redmile Group
  221. Redx Pharma
  222. Regis Technologies
  223. Rhône-Alpes Création
  224. RiverVest Venture Partners
  225. Rock Springs Capital
  226. Roswell Park Cancer Institute
  227. Samsung Biologics
  228. Sanofi
  229. Schering Plough Brinny Co.
  230. Scottish Venture Fund
  231. Seattle Genetics
  232. Sequoia Capital
  233. Servier
  234. Seventure Partners
  235. SHAM
  236. Sharp & Dohme Corp.
  237. Sidney Kimmel Comprehensive Cancer Center
  238. Singapore BioInnovations
  239. Society of Melanoma Research International Congress 
  240. Sorrento Therapeutics
  241. Southwest Oncology Group
  242. Spring Bioscience
  243. Syndax Pharmaceuticals
  244. Synta Pharmaceuticals
  245. Takara Bio Inc.
  246. Tavistock Life Sciences
  247. Tesaro
  248. TetraLogic Pharmaceuticals
  249. Texas Pacific Group  Ventures
  250. TG Therapeutics
  251. The Leukemia and Lymphoma Society
  252. The University of Texas MD Anderson Cancer Center
  253. The Wellcome Trust
  254. Theravectys
  255. Third Rock Ventures
  256. Thomas Jefferson University
  257. Thuja Capital Healthcare Funds
  258. ToleroTech
  259. Tolerx
  260. TPG Ventures
  261. Transparency Commission
  262. Université Catholique de Louvain
  263. United Therapeutics
  264. University Hospital Southampton NHS Foundation Trust
  265. University of California, Davis
  266. University of Iowa Pharmaceutical Services
  267. University of Minnesota
  268. University of Pittsburgh
  269. University of Texas
  270. University of Utah
  271. Ventana Medical Systems
  272. Ventures West
  273. Versant Ventures
  274. Vlaams Instituut voor Biotechnologie
  275. Vinnova
  276. Viralytics
  277. VIVES Louvain Technology Fund
  278. Vivo Ventures
  279. VLST Corporation
  280. Walloon
  281. Washington University School of Medicine
  282. Wellcome Trust Sanger Institute
  283. Wellington Management
  284. WS Investments
  285. Wyeth 

PRICING DETAILS

USD 2,199

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.